A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist–Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH)

A randomized trial (the Alberta Vascular Risk Reduction Community Pharmacy Project) showed that a community pharmacist-led intervention was efficacious for reducing cardiovascular (CV) risk. However, the cost of this strategy is unknown. We examined the short- and long-term cost of a pharmacist-led intervention to reduce CV risk compared to usual care. We conducted a trial-based cost analysis from the perspective of a publicly funded healthcare system. Over 3 and 12 months of follow-up, we examined specific intervention costs (pharmacy claims), related intervention costs (laboratory tests and medications), and ongoing healthcare costs (physician claims, emergency department visits, and hospital admissions). We also used the validated CV Disease Policy Model–Canada to estimate the long-term effects. A total of 684 participants (mean age 62, 57% male) were included. Overall, there were no significant differences in healthcare costs at 3 or 12 months between the usual care and intervention groups (P = .127). The CV disease-related healthcare cost of managing a patient over a lifetime was estimated to be Can$45 530 (95% uncertainty interval [UI], 45 460-45 580) and Can$40 750 (95% UI, 37 780-43 620) in usual care and intervention groups, respectively, an incremental cost savings of Can$4770 per patient (95% UI, 1900-7760). The intervention dominated usual care (better outcomes and lower costs) across 3-year, 5-year, 10-year, and lifetime horizons. This economic analysis suggests that a clinical pathway-driven pharmacist-led intervention (previously shown to reduce CV risk) was associated with similar measured healthcare costs over 1 year, and lower extrapolated healthcare costs over a patient lifetime. This strategy could be broadly implemented to realize its benefits. •The Alberta Vascular Risk Reduction Community Pharmacy Project, RxEACH, was a randomized trial in Alberta, Canada, which showed a clinical pathway-driven community pharmacist-led intervention was efficacious for reducing cardiovascular (CV) risk.•Nevertheless, the cost of this strategy is unknown.•We found no significant difference in short-term healthcare cost between the intervention and usual care groups.•Over a lifetime, the clinical pathway-driven pharmacist-led intervention was estimated to save almost $5000 in CV disease-related healthcare costs per patient at high risk for CV disease.•This economic analysis suggests that a clinical pathway-driven pharmacist-led intervention (previously